Press time:2016-08-26From:CR Saike [ Font:BigMediumSmall]
Pfizer International Trading Ltd. (below as Pfizer) and China Resources Saike Pharmaceutical Co.,Ltd.(below as Saike) have signed up the Agreement on August 23rd,2016 formally. Saike is thus authorized to be the exclusive importer and distributor for Nitrostat (Nitroglycerin Sublingual Tablets) in mainland China. Furthermore, both parties are open-minded about the probability of repacking for Nitrostat by Saike.
This is Saike’s third collaboration with Pfizer after Fragmin and Sermion. Nitrostat project not only strengthens the commercial cooperation between both parties, but also further deepening the strategic partnership on the basis of mutual trust and benefit. Commercialization of Pfizer's products has been conducive to promoting Saike to accelerate its transformation and enhance its academic promotion capability. Meanwhile, Nitrostat's cooperation will make Saike become the first import repackaging contractor of Pfizer in mainland China.
Nitroglycerin Tablet is the first and best choice for the treatment of acute episode of coronary heart disease, and the only emergency medicine recommended by both domestic and international guidelines. Nitrostat was developed by Pfizer as sublingual tablet by using patented formulation and process to solve nitroglycerin’s volatile characteristics and thus to make nitroglycerin stabilize. Meanwhile, disintegrating agent used in this product will make its disintegration more rapidly. The cooperation between Pfizer and Saike will fulfill the unmet need in the domestic high-end market for nitroglycerin, and therefore will provide Chinese patients with the new and best choice for acute episode of cardiovascular events.
Currently, Nitrostat enjoys the top sales among all the nitroglycerin preparations in the U.S., with sales of up to $200 million in the United States in 2015.
